Hjem › Steatotisk leversykdom › Virginia › Richmond
Kliniske studier for Steatotisk leversykdom i Richmond, VA
12 studier for Steatotisk leversykdom søker deltakere på steder i og rundt Richmond (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
RekruttererFase 3
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
RekruttererFase 3
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RekruttererFase 2
- Virginia Commonwealth University, Richmond
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
RekruttererFase 2
- Richmond Veterans Administration Medical Center, Richmond
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
RekruttererFase 3
- Richmond Veterans Affairs Medical Center (Richmond VA Medical Center), Richmond
- Virginia Commonwealth University (VCU) Medical Center, Richmond
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RekruttererFase 3
- Akero Clinical Study Site, Richmond
- Akero Clinical Study Site, Richmond
- Akero Clinical Study Site, Richmond
- og 1 flere
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
RekruttererFase 2
- GI Alliance Richmond, Richmond
- GI Select Health Research, Richmond
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
RekruttererFase 2
- GSK Investigational Site, Richmond
- GSK Investigational Site, Richmond
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
RekruttererFase 2
- GSK Investigational Site, Richmond
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
RekruttererFase 2
- Virginia Commonwealth University, Richmond
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
Rekrutterer
- Virginia Common wealth University, Richmond
Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
RekruttererObservasjonsstudie
- Virginia Commonwealth University, Richmond
Steatotisk leversykdom-studier i andre byer
- San Antonio, TX17 studier
- New York City, NY16 studier
- Miami, FL16 studier
- San Diego, CA14 studier
- Austin, TX13 studier
- Houston, TX13 studier
- Tucson, AZ10 studier
- Chandler, AZ10 studier
- Hialeah, FL9 studier
- Dallas, TX9 studier
- Orlando, FL9 studier
- St. Louis, MO9 studier
Andre studier i Richmond
- Brystkreft26 studier
- Ikke-småcellet lungekreft25 studier
- Prostatakreft19 studier
- Hjertesvikt16 studier
- Lungekreft14 studier
- Kardiovaskulær sykdom13 studier
- Kolorektal kreft13 studier
- Akut myelogen leukemi12 studier
- Metastatisk kreft12 studier
- Plateepitelcancer i hode og hals12 studier
- Melanom11 studier
- Fedme11 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.